Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma

Full article: Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness

T cells infiltrate PDA regardless of GM-CSF expression. A-C) IHC of

Ibrutinib Single-handedly Impacts Immune Environment in Metastatic PDAC

Scientific rationale for integrative and personalised strategies for pancreatic ductal adenocarcinoma management

Vaccines, Free Full-Text

Cancers, Free Full-Text

Sulfonamides as tyrosine kinase modulators – A promising class of anticancer agents - ScienceDirect

The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy - The Lancet Gastroenterology & Hepatology

Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies - Anthony Turpin, Cindy Neuzillet, Elise Colle, Nelson Dusetti, Rémy Nicolle, Jérôme Cros, Louis de Mestier, Jean-Baptiste Bachet, Pascal Hammel, 2022

Envisioning the immune system to determine its role in pancreatic ductal adenocarcinoma: Culprit or victim? - ScienceDirect

The recent progress of myeloid‐derived suppressor cell and its targeted therapies in cancers - Ren - 2023 - MedComm - Wiley Online Library

Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective

M1 Macrophage-Derived Nanovesicles Potentiate the Anticancer Efficacy of Immune Checkpoint Inhibitors